Kuria Therapeutics Inc. has closed its first fundraising round to support ongoing preclinical development activities ahead of a planned series A raise.
Laverock Therapeutics Ltd. (formerly Skylark Therapeutics) recently completed a seed funding round to support its development of a unique gene silencing platform for the creation of programmable, allogeneic cell therapies.
RSS